Passage Bio Balance Sheet Health
Financial Health criteria checks 6/6
Passage Bio has a total shareholder equity of $90.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $125.4M and $34.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$91.77m |
| Equity | US$90.56m |
| Total liabilities | US$34.84m |
| Total assets | US$125.39m |
Recent financial health updates
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Sep 24
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Jun 11We're Keeping An Eye On Passage Bio's (NASDAQ:PASG) Cash Burn Rate
Feb 27Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Nov 13Recent updates
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Sep 24Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Jun 11We're Keeping An Eye On Passage Bio's (NASDAQ:PASG) Cash Burn Rate
Feb 27Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Nov 13We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully
Jun 23Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?
Nov 13Passage appoints William Chou CEO
Oct 10Passage Bio GAAP EPS of -$0.73 beats by $0.09
Aug 04We're A Little Worried About Passage Bio's (NASDAQ:PASG) Cash Burn Rate
Jun 03Passage Bio: Worth Keeping An Eye On
Apr 11Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?
Dec 15Passage Bio (NASDAQ:PASG) Is In A Good Position To Deliver On Growth Plans
Aug 19Passage Bio: Price Reduced, But Without Data, Does Not Look Convincing
Jun 06Passage Bio partners with InformedDNA to offer counseling, testing for early dementia
May 03We're Hopeful That Passage Bio (NASDAQ:PASG) Will Use Its Cash Wisely
Mar 08Do Institutions Own Passage Bio, Inc. (NASDAQ:PASG) Shares?
Feb 01
Passage Bio on go with PBGM01 gene therapy trial in the U.S.
Jan 04Need To Know: Passage Bio, Inc. (NASDAQ:PASG) Insiders Have Been Buying Shares
Dec 28U.K. authorizes Passage Bio's PBGM01 trial
Dec 10Passage Bio (PASG) Investor Presentation - Slideshow
Nov 16Passage Bio EPS beats by $0.13
Nov 10Passage Bio’s PBKR03 nabs Orphan drug tag and accelerated review status for Krabbe disease
Oct 28Financial Position Analysis
Short Term Liabilities: PASG's short term assets ($95.0M) exceed its short term liabilities ($12.4M).
Long Term Liabilities: PASG's short term assets ($95.0M) exceed its long term liabilities ($22.5M).
Debt to Equity History and Analysis
Debt Level: PASG is debt free.
Reducing Debt: PASG has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PASG has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PASG has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 10.9% each year.